N@N

NewCardio Selected to Make Presentations at 32nd Annual International Conference of the IEEE Engineering in Medicine and Biolog

^{Published on 2010-06-14 07:20:14 - Market Wire}
 

SANTA CLARA, Calif.--([ BUSINESS WIRE ])--NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider, announced today that two of its recent medical and technical submissions have been accepted for presentation at the 32^nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society conference. The two papers: aWireless Transmission of Reconstructed 12-Lead ECGs in the Remote Monitoring of Atrial Fibrillationa and aWireless Remote Monitoring of Myocardial Ischemia Using Reconstructed 12-Lead ECGsa will be presented during the conference to be held August 31^st through September 4^th, 2010, in Buenos Aires, Argentina.

"Wireless Transmission of Reconstructed 12-Lead ECGs in the Remote Monitoring of Atrial Fibrillation"

NewCardio scientists and their academic medical collaborators will present data from two full clinical studies showing that CardioBipa" accurately captured, wirelessly transmitted, and reconstructed full 12-lead ECG data from two distinct patient groups: (1) patients with coronary artery disease (CAD) with significant risk for myocardial infarction, i.e. a heart attack, and (2) patients with atrial fibrillation (AF), who are at significant risk for stroke because of recurrent bouts of AF. CardioBip is a unique, hand held device that provides for accurate and timely diagnoses of acute cardiac events, and facilitates immediate intervention in life-threatening situations a" even when the patient is far removed from a medical care center. Images of the CardioBip are available at [ www.newcardio.com/products-cardio-bip.php. ]

"This now marks the second very prestigious medical conference that has accepted two of our papers for presentation this year. The acceptance of these submissions reflects the growing interest in telemedicine and the recognition that our science and technology solutions are gaining acceptance in the industry because of their quality and innovative nature, and because they meet important and previously underserved needs,a stated NewCardio CEO Branislav Vajdic, PhD.

Medical experts increasingly recognize the need for long-term outpatient monitoring of such patients, and the Company believes the clinical study results that will be presented at the IEEE Conference indicate that CardioBip is well-suited to fill this unmet medical need.

The conference program will consist of plenary lectures, symposia, workshops and invited sessions of the latest significant findings and developments in all the major fields of biomedical engineering. Submitted papers will be peer reviewed. Accepted high quality papers will be presented in oral and poster sessions, will appear in the Conference Proceedings and will be indexed in PubMed/MEDLINE.

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead ECG. NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit [ www.newcardio.com ].

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link: [ http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0 ]